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OBJECTIVES This study was designed to examine the differential effects of a- and g-tocopherol on
parameters of oxidation-antioxidation and thrombogenesis.
BACKGROUND Experimental studies have shown that antioxidants, such as vitamin E (a-tocopherol),
improve atherosclerotic plaque stability and vasomotor function, and decrease platelet
aggregation and tendency to thrombus formation.
METHODS Sprague Dawley rats were fed chow mixed with a- or g-tocopherol (100 mg/kg/day) for 10
days. A filter soaked in 29% FeCl3 was applied around the abdominal aorta to study the
patterns of arterial thrombosis. The aortic blood flow was observed and continuously recorded
using an ultrasonic Doppler flow probe. ADP-induced platelet aggregation, low-density
lipoprotein oxidation induced by phorbol 12-myristate 13-acetate (PMA)-stimulated leuko-
cytes, superoxide anion generation and superoxide dismutase (SOD) activity were also
measured.
RESULTS Both a- and g-tocopherol decreased platelet aggregation and delayed time to occlusive
thrombus (all p , 0.05 vs. control). Both a- and g-tocopherol decreased arterial superoxide
anion generation, lipid peroxidation and LDL oxidation (all p , 0.05 vs. control), and
increased endogenous SOD activity (p , 0.05). The effects of g-tocopherol were more potent
than those of a-tocopherol (p , 0.05).
CONCLUSIONS This study indicates that both a- and g-tocopherol decrease platelet aggregation and delay
intraarterial thrombus formation, perhaps by an increase in endogenous antioxidant activity.
g-Tocopherol is significantly more potent than a-tocopherol in these effects. (J Am Coll
Cardiol 1999;34:1208–15) © 1999 by the American College of Cardiology
Epidemiological studies (1–3) have provided evidence for an
inverse relation between acute coronary events and antiox-
idant vitamin intake. Dietary supplementation with vitamin
E, in particular, has been shown to reduce the number of
ischemic cardiac events in patients with documented coro-
nary artery disease (CAD) in one prospective study (4).
See page 1216
There is evidence that plaque stability, vasomotor function,
platelet aggregation and tendency to thrombosis can be
modified by antioxidants (5). Antioxidants inhibit monocyte
adhesion, protect against the cytotoxic effects of oxidized
low-density lipoprotein (LDL) and reduce platelet activa-
tion (5). Vitamin E and antioxidant probucol also protect
against endothelial dysfunction associated with atheroscle-
rosis by preserving endothelium-derived nitric oxide (NO)
activity (6,7). It is now generally recognized that platelet
aggregation is abnormally increased in CAD patients (8,9).
Experimental studies have shown that free radicals promote
platelet aggregation and thrombosis (10,11) and chain
breaking antioxidants, such as vitamin E, inhibit or delay
arterial thrombogenesis (12).
NO, formed as a result of the action of constitutive NO
synthase (cNOS) enzyme on L-arginine, is a powerful
vasodilator and platelet aggregation inhibitor (13). Nitric
oxide reacts with superoxide at near diffusion-limited rates
to form peroxynitrite, another reactive oxygen intermediate,
which can lead to the formation of hydroxyl and singlet
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oxygen radicals (14). Vitamin E has been shown to enhance
NO-dependent vasorelaxation (6) and decrease platelet
aggregation (15), presumably related to inhibition of free
radicals.
Vitamin E consists of two major different structural
forms: a- and g-tocopherol. In recent in vitro studies,
g-tocopherol has been shown to inhibit lipid peroxidative
damage (16) and to trap mutagenic electrophiles (17) more
efficiently than a-tocopherol. Further, it is the g-tocopherol,
and not a-tocopherol, that appears to be expressed in low
amounts in the plasma of patients with CAD (18). A
clinical study has shown that dietary supplementation with
a-tocopherol, the primary form of vitamin E in commercial
preparations, may further lower plasma g-tocopherol levels
(19). As such, dietary supplementation with a- and
g-tocopherol may have different biological effects.
Because of the potential differences in the antioxidant
effect of a- and g-tocopherol that may influence intravas-
cular thrombus formation, we hypothesized that the two
vitamin E formulations may have different effects on platelet
aggregation and arterial thrombogenesis. This study was
designed to explore these issues.
MATERIALS AND METHODS
Thirty-three male Sprague Dawley rats (weight 300 to
350 g) were used in this study. The rats were randomly fed
regular rat chow mixed with rapeseed oil (800 mg/kg/day,
n 5 11), or chow and rapeseed oil mixed with a-tocopherol
(Covitol F; Henkel, Dusseldorf, Germany), or g-tocopherol
(Cardinova, Uppsala, Sweden) (100 mg/kg/day each, n 5
11 in each group) for 7 to 10 days. At the end of the feeding
period, thrombogenesis was examined in all rats, and blood
and aortic tissues were harvested for measurements de-
scribed below. This study was approved by the appropriate
Institutional Animal Care Committees.
Model of arterial thrombosis. An arterial thrombus model
initially described by Kurtz et al. (20), and subsequently by
us (21), was used in this study. In brief, animals were
anesthetized with sodium pentobarbital (30 mg/kg). The
abdominal cavity was opened and approximately 1.2 cm of
the abdominal aorta was isolated. The aortic blood flow was
observed for 1 h and continuously recorded using an
ultrasonic Doppler flow probe (Crystal Biotech, Holliston,
MA).
Whatman paper soaked in 29% FeCl3 was wrapped
around the external surface of the aorta. After the thrombus
was formed, the exposed aorta was removed and the
thrombus was weighed. Blood was collected for measuring
plasma a- and g-tocopherol levels, superoxide dismutase
(SOD) activity and determination of platelet aggregation.
The abdominal aorta proximal to the thrombus was saved
for measurement of superoxide anion generation, lipid
peroxidative product malondialdehyde (MDA) and SOD
activity. Leukocytes from five normal rats on regular chow
were used to study oxidation of LDL.
Measurement of a- and g-tocopherol in plasma. Plasma
levels of a- and g-tocopherol were measured by high-
performance liquid chromatography with fluorescence de-
tection, as described earlier (22).
Platelet aggregation. Blood was gently mixed with 3.8%
sodium citrate (9:1), centrifuged at 1,200 rpm for 10 min at
room temperature to obtain platelet-rich plasma (PRP) and
centrifuged again at 3,000 rpm for 15 min to obtain
platelet-poor plasma. Platelet count in PRP was counted
and kept at about 2 to 3 3 108cells/ml. ADP (final
concentration 20 mM) was used as stimulus for platelet
aggregation. This concentration of ADP has been used in
several experiments in our laboratory (12,21,23). All aggre-
gations were conducted in a four-channel aggregometer
(BIO/DATA, Horsham, Pennsylvania) in duplicate.
Determination of SOD activity. SOD activity in plasma
and aortic homogenates, as an index of endogenous antiox-
idant activity, was measured spectrophotometrically in du-
plicate by monitoring the SOD-inhabitable autooxidation
of pyrogallol, as described in our previous study (24). The
reaction mixture (4.5 ml) consisted of 0.2 mmol/L of
pyrogallol, 1 mmol/L of diethylenetriamine penta-acetic
acid, 50 mmol/L of tris-cacodylic acid buffer (pH 8.2) and
4 mg of catalase. The reaction was carried out at 25°C. The
rate of increase in absorbance at 420 nm was recorded. One
unit of enzyme activity is defined as 50% inhibition of
pyrogallol autooxidation under the assay conditions. The
SOD activity was expressed as units per milliliter in plasma
and units per milligram protein in aortic homogenates.
Arterial superoxide anion generation. An approximately
0.6-cm segment of abdominal aorta proximal to the throm-
bus was excised, and placed in oxygen-saturated Krebs-
Ringer buffer, cleaned of fat and loose connective tissue.
Care was taken to avoid any unnecessary manipulation of
the vessel. The rate of superoxide anion formation by
abdominal aortic segments was determined by chemilumi-
nescence of lucigenin (bis-N-methyl-acridinium nitrate), as
described recently (25). Briefly, Krebs-Ringer buffer con-
taining 0.25 mM lucigenin (pH 7.4) was prepared as an
assay solution. One milliliter of this assay solution was
placed in a glass scintillation vial, and then an aortic
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segment was gently placed in the assay solution. The
chemiluminescence of lucigenin was then detected with the
use of a scintillation counter (LS 7000; Beckman, Irvine,
California) in out-of-coincidence mode with a single active
photomultiplier tube every 3 min. The chemical specificity
of this light-yielding reaction for superoxide anion has been
reported previously, and the sensitivity and specificity of this
assay was determined with xanthine (100 to 400 nM) and
xanthine (0.002 U) to generate superoxide anion with or
without SOD (25). The data on superoxide anion genera-
tion was expressed as counts per minute per milligram
(cpm/mg).
Determination of lipid peroxidation (MDA). MDA for-
mation was measured in the plasma as index of lipid
peroxidation, as described earlier (24). The assay mixture
consisted of 0.1 ml of plasma or supernatant of aortic
homogenate, 0.4 ml of 0.9% NaCl, 0.5 ml of 3% sodium
dodecylsulfate, 3 ml of thiobarbituric acid reagent (contain-
ing equal parts of 0.8% aqueous thiobarbituric acid and
acetic acid), and was heated for 75 min at 95°C. Thereafter,
1 ml cold 0.9% NaCl was added to the mixture, which was
cooled and extracted with 5 ml n-butanol. After centrifu-
gation at 3,000 rpm for 15 min, the butanol phase was
assayed spectrophotometrically at 532 nm. MDA (in
amounts of 0, 0.1, 0.2, 0.4, 0.8, and 1 nmol) served as
external standard. Malondialdehyde content in the plasma
was expressed as nanomoles per milliliter.
a- and g-tocopherol and LDL oxidation. To examine the
effect of a- and g-tocopherol on LDL oxidation, native
LDL (50 mg/ml) was incubated with rat leukocytes (106
cells/ml) and phorbol 12-myristate 13-acetate (PMA) (100
ng/ml) in 2 ml of Tyrode’s buffer (mmol/L:NaCl 137, KCl
2.7, MgCl2 1.0, CaCl2 1.0, NaH2PO4 0.35, NaHCO3 11.9
and glucose 5.5, pH 6.5) with or without 100 ml of plasma
from rats fed regular diet or a- and g-tocopherol-rich diet.
After 1 h of incubation at 37°C, kinetics of LDL oxidation
in the supernate were determined by monitoring the change
in absorbance (234 nm) in an ultraviolet spectrophotometer
(Shimadzu, Kyoto, Japan). Absorbance was recorded every
hour for 6 h. From the kinetic absorbance profile of each
experiment, the rate of oxidation was calculated from the
slope of absorbance curve during the propagation phase,
expressed as nmoles dienes/min per mg LDL protein (22).
The methods for isolation of leukocytes and native LDL
have been described earlier (22).
Statistical analysis. All data represent the mean of dupli-
cate samples from at least five independently performed
experiments. Data are presented as mean 6 SD. Statistical
significance in multiple comparisons was determined among
independent groups of data in which analysis of variance
(ANOVA) followed by Fisher’s exact test indicated the
presence of significant differences. A p value , 0.05 was
considered significant.
RESULTS
Plasma a- and g-tocopherol levels. Plasma a-tocopherol
levels were markedly higher in a-tocopherol-fed rats (p ,
0.01 as compared with control or g-tocopherol-fed rats).
The g-tocopherol levels were very low in the control group
of rats and decreased further in the a-tocopherol-fed rats.
On the other hand, plasma g-tocopherol levels were mark-
edly elevated in g-tocopherol-fed rats, while a-tocopherol
levels in these rats were comparable with the control rats
(Fig. 1).
Figure 1. Plasma levels of a- and g-tocopherol in rats fed different diets. Plasma a-tocopherol levels increased markedly in
a-tocopherol-fed rats, and g-tocopherol levels decreased as compared with the control rats. On the other hand, plasma g-tocopherol levels
were markedly elevated in g-tocopherol-fed rats, and a-tocopherol levels were not different as compared with control rats. a-T 5
a-tocopherol; g-T 5 g-tocopherol. Data are mean 6 SD (n 5 11 rats in each group).
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Time to thrombosis and platelet aggregation. Applica-
tion of FeCl3 in control rats resulted in oscillations in aortic
blood flow for about 15 to 20 min. This was followed by a
rapid decrease in blood flow and eventually total cessation,
indicating occlusive thrombus formation. During the 60-
min period of observation, there was no evidence of return
of flow in any of the control animals.
In rats fed a-tocopherol, the time to thrombus formation
was increased 25% (p , 0.05 as compared with control rats).
In rats fed g-tocopherol, thrombus could not be formed
over the entire 1-h period of observation in one animal, and
the time to thrombus formation was 58% longer in the
remaining 10 rats than in control rats (p , 0.01). The time
to thrombus formation was longer in g-tocopherol-fed rats
than in the a-tocopherol-fed rats (p , 0.05). In contrast to
stable thrombus in the control rats, the thrombus was
unstable in three of 11 a-tocopherol-fed rats, as indicated
by spontaneous return of blood flow during the period of
observation. The thrombus was unstable in 6 of 10
g-tocopherol-fed rats, as indicated by spontaneous return of
blood flow during the one-hour period of observation.
Representative patterns of thrombus formation in the
three groups of rats are shown in Figure 2, and the
summary of data on thrombogenesis in all animals are
presented in Figure 3.
Platelet aggregation was less in rats fed a- or g-tocopherol
(p , 0.05 as compared with control rats). The inhibition of
platelet aggregation was greater in g-tocopherol-fed rats
than in the a-tocopherol-fed rats (p , 0.05) (Fig. 3).
Oxidation of LDL. Plasma from both a- or g-tocopherol-
fed rats significantly decreased the rate of LDL oxidation
induced by PMA-stimulated leukocytes (p , 0.05 vs.
control rats). g-Tocopherol was significantly more potent in
reducing oxidizability of LDL than was a-tocopherol (p ,
0.05) (Fig. 4).
Superoxide anion generation and lipid peroxidation.
Arterial superoxide anion generation was 19,800 6
2,400 cpm/mg in the control rats. This value was reduced by
28% in the a-tocopherol-fed rats and by 49% in the
g-tocopherol-fed rats (both p , 0.05 vs. control rats). The
superoxide anion generation in the g-tocopherol-fed rats
was markedly less than in a-tocopherol-fed rats (Fig. 5).
Plasma MDA, a lipid peroxidation product, was also
decreased in both a- or g-tocopherol-fed rats (p , 0.05 vs.
control rats). Plasma MDA in the g-tocopherol-fed rats was
less than that in the a-tocopherol-fed rats (p , 0.05) (Fig. 5).
SOD activity. Administration of a- or g-tocopherol sig-
nificantly increased SOD activity in aortic homogenates as
well as in plasma (p , 0.05 vs. control rats). Feeding of
g-tocopherol to rats caused greater effect on SOD activity
than feeding of a-tocopherol (p , 0.05) (Fig. 6).
DISCUSSION
This study demonstrates that both a- and g-tocopherol
significantly decrease platelet aggregation and delay the time
to occlusive thrombus formation. Both a- and g-tocopherol
markedly decrease arterial superoxide anion generation,
lipid peroxidation and LDL oxidation. Interestingly, both
a- and g-tocopherol also increase endogenous SOD activity
in different tissues. Importantly, we found that g-tocopherol
was more potent than a-tocopherol in all these effects.
Figure 2. Representative examples of thrombus formation in rats from control group, a-tocopherol and g-tocopherol group. The time to
thrombus formation, as indicated by cessation of flow, is 9 min longer in a-tocopherol fed rat, whereas thrombus formation is delayed
markedly in the g-tocopherol group. Please note the initial decrease in aortic flow in the rat from the g-tocopherol group suggesting
platelet aggregation; however, the flow is quickly restored suggesting break of the platelet aggregates.
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Before discussing these results, a comment needs to be
made relative to the thrombus model used in this study. In
this rat model, the thrombus is formed rapidly (15 to
25 min) in response to application of FeCl3, and is charac-
terized by endothelial disruption, extensive platelet and red
blood cell clumps and interspersed fibrin (20,21). This
morphology of the thrombus is similar to the thrombi in the
coronary arteries of patients with acute myocardial ischemia
(26). The low cost of the animals, ease of thrombus
formation and similarity to human thrombus make the rat
model unique to the study of influence of different agents
that can inhibit platelet aggregation and thrombosis. FeCl3
causes oxidative injury to the endothelium, which facilitates
platelet deposition to the subendothelial layers, and the
effects of vitamin E may reflect its potent antioxidant effect.
Similar antithrombotic effects of vitamin E have been
shown in non-FeCl3-induced thrombosis models (10,11).
Antioxidant vitamins and thrombosis. Clinical and
pathological studies have shown that disruption or erosion
of atherosclerotic plaque is the major cause of coronary
thrombosis, which is the basis of precipitation of acute
coronary syndromes (8,9). Atherosclerosis and thrombosis
are associated with many common pathological features,
such as deposition and aggregation of platelets, monocyte/
macrophage infiltration and dysfunctional endothelium.
Furthermore, both these conditions are associated with
increased oxidative stress (8,27). Atherosclerotic lesion for-
mation is associated with accumulation of lipid peroxidation
products and the induction of inflammatory genes by
NF-kB, a redox-sensitive transcription factor (28). Vitamin
E and other antioxidants have been shown to reduce
thrombus formation (10,12), extent of atherosclerosis in
cholesterol-fed animals (23) and the incidence of acute
cardiac events in men and women (1–3). The impaired
endothelium-dependent relaxation accompanying the ath-
erosclerotic process can be restored with administration of
vitamin E and the antioxidant probucol (6,7). Recent
studies show that vitamin E inhibits platelet aggregation by
a protein kinase C-dependent mechanism (15). In the
present study, we demonstrate that both a- and g-tocopherol
significantly inhibit platelet aggregation and delay thrombus
formation in the rat. Interestingly, we found that both a-
and g-tocopherol affect the stability of arterial thrombus,
suggesting an increase in the endogenous thrombolytic
potential by both vitamin E preparations. It is possible that
inhibition of platelet aggregation and thrombosis is the
major mechanism by which vitamin E decreases the fre-
quency of acute cardiac events in patients with preexisting
CAD (4).
a- and g-tocopherol, free radicals and thrombosis. Nu-
merous experimental studies suggest a major role for
oxygen-free radicals in the pathogenesis of the myocardial
Figure 4. Oxidation of LDL by PMA-stimulated leukocytes in
the presence of rat plasma. Administration of a- or g-tocopherol
to rats significantly decreased the rate of oxidation induced by
PMA-stimulated leukocytes (p , 0.05 vs. control rats).
g-Tocopherol had stronger effect in reducing oxidizability of LDL
than a-tocopherol (p , 0.05). Data (mean 6 SD) shown are from
five separate experiments.
Figure 3. Summary of data on time to thrombus formation and platelet aggregation in rats from control group, a-tocopherol and
g-tocopherol group. Data (mean 6 SD) shown are from 11 rats in the control group, 11 rats in the a-tocopherol group and 10 rats in
the g-tocopherol group
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lesions observed during the process of ischemia-reperfusion.
Free radicals promote platelet aggregation, injure endothe-
lium and enhance intravascular thrombus formation (10–
12,29). Jourdan et al. (11) showed induction of thrombus by
free radicals in rats and an antithrombotic effect of vitamin
E on thrombus formation induced by free radicals. An
earlier study from our laboratory (30) showed that the
antioxidant SOD when administered before tissue plasmin-
ogen activator (t-PA) prevented coronary artery reocclusion
after thrombolysis in a canine model of coronary artery
thrombosis. Ikeda et al. (10) found that SOD plus catalase
reduced cyclic flow variations in narrowed coronary arteries
of dog coronary artery. These cyclic flow reductions are
thought to be caused by platelet aggregation occurring in
blood vessels with dysfunctional endothelium. Przyklenk
and Kloner (31) also showed that administration of antioxi-
dants inhibits platelet aggregation and promotes thrombo-
lytic effect of t-PA. Nunes et al. (32) showed that neointi-
mal proliferation after balloon angioplasty of pig coronary
arteries is accompanied by an increased production of
superoxide anions, apparently by smooth muscle cells and
fibroblasts in the vessel wall. This increase in superoxide
anions was attenuated when pigs were pretreated with
vitamin C, vitamin E or their combination for seven days
before angioplasty. These data collectively indicate that
reactive oxygen species released from vessel wall and blood
constituents cause platelet aggregation, intimal proliferation
and thrombosis. In the present study, we found that both a-
and g-tocopherol significantly reduced superoxide anion
generation and lipid peroxidation product MDA. These
data may have implications relative to improvement in
endothelial function, reduction in platelet aggregation and
inhibition of thrombosis after therapy with vitamin E.
a- and g-tocopherol and SOD activity. In two recent
studies, one in rats fed a high-fructose diet (33) and the
other in rabbits given a high-cholesterol diet (22), admin-
istration of vitamin E was associated with an increase in
SOD activity. In another study (34), Martin et al. found
that vitamin E supplementation significantly increases SOD
and catalase activity in aortic endothelial cells. In the current
study, we demonstrate that both a- and g-tocopherol
significantly increase SOD activity in plasma as well as in
the aortic tissues. These findings may also have relevance in
inhibition of platelet aggregation, prolongation of time to
thrombosis and instability of the thrombus. This hypothesis
is consistent with the well-known effects of SOD on platelet
aggregation and thrombogenesis (10,30,31).
Antioxidant vitamins and atherosclerosis. The oxidative-
modification hypothesis implies that it is the oxidatively
modified LDL that is relevant in atherogenesis (5). There is
evidence that plaque stability, vasomotor function and
tendency to thrombosis are subject to modification by
specific antioxidants. For example, cellular antioxidants
inhibit monocyte adhesion, protect against the cytotoxic
effects of oxidized-LDL and inhibit platelet activation. It is
widely appreciated that LDL, especially its oxidatively
modified form, oxidized-LDL, is a critical factor in athero-
Figure 5. Summary of data on arterial superoxide generation and plasma MDA levels. Data (mean 6 SD) shown are from 11 rats in the
control group, 11 rats in the a-tocopherol group and 11 rats in the g-tocopherol group
Figure 6. SOD activity in aortic homogenates and plasma from
rats fed different diets. Feeding of rats with a- and g-tocopherol
increased SOD activity in the supernatants of aortic homogenates
and in the plasma. Data (mean 6 SD) shown are from 11 rats in
the control group, 11 rats in the a-tocopherol group and 11 rats in
the g-tocopherol group.
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genesis and platelet aggregation (35,36). Ox-LDL has also
been implicated in the pathogenesis of acute myocardial
infarction (37). The endothelial dysfunction and increased
platelet aggregation are present before and throughout the
development of atherosclerosis and particularly during
plaque rupture. Studies (24,35) from our laboratory have
shown that ox-LDL causes human coronary artery endo-
thelial cell injury (by apoptosis and necrosis) as well as
platelet aggregation (by inhibition of NO synthase activity).
In the current study, we used PMA to induce leukocytes to
release free radicals, and the latter causes LDL oxidation.
We found that plasma from a and g-tocopherol-fed rats
significantly reduced oxidation of LDL. Additional evidence
for the antioxidant effect of a- and g-tocopherol came from
reduction in MDA levels in plasma of rats. These potent
antioxidant effects may underlie the attenuation of thrombus
formation by vitamin E. These observations collectively sug-
gest that the protective effects of a- and g-tocopherol against
progression of atherosclerosis and thrombus formation may
relate to reduction of LDL oxidation.
Greater efficacy of g-tocopherol than a-tocopherol. In
this study, we demonstrate that g-tocopherol is significantly
more potent than a-tocopherol in inhibiting platelet ag-
gregation and thrombogenesis. We also found that
g-tocopherol reduced superoxide anion generation, lipid
peroxidation and LDL oxidation, and increased SOD
activity to a much greater extent than a-tocopherol.
The harmful effect of free radicals is best counteracted by
g-tocopherol and to a lesser extent by a-tocopherol (16,17).
An in vitro study (38) has even suggested that a-tocopherol
may become prooxidant in large concentrations; however, we
did not observe any evidence of prooxidant effect of feeding
a-tocopherol to the rats. Several pieces of evidence suggest that
g-tocopherol, when taken as part of diet, may be more
important than a-tocopherol in the prevention of CAD-
associated morbidity (3). Incidentally, it is the g-tocopherol
levels that are low in plasma, whereas a-tocopherol levels are in
the normal range, in CAD patients (18).
Summary. This study shows that both a- and g-tocopherol
inhibit platelet aggregation and delay arterial thrombus
formation in rats. Dietary supplementation with a- and
g-tocopherol in rats also reduced superoxide generation,
lipid peroxidation and LDL oxidation, and increased SOD
activity. Importantly, g-tocopherol was more potent than
a-tocopherol in all these effects. The clinical implications of
these findings are enormous in terms of recommending
supplementation of commercial antioxidant preparations
with g-tocopherol to patients with vascular disease or those
at high risk of developing it.
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